Divarasib extended median overall survival to 17.7 months vs 12.0 months with sotorasib or adagrasib in the Krascendo 1 trial, with new olomorasib and daraxonrasib data close behin

Oncology Nursing News· @OncNursingNews · X·2026-10-26 23:21· 4 小时前评分70

正文 · 原文

Divarasib extended median overall survival to 17.7 months vs 12.0 months with sotorasib or adagrasib in the Krascendo 1 trial, with new olomorasib and daraxonrasib data close behind: https://hubs.li/Q04Cj2Jg0 #OncologyNursing #OncNurse #ESMO26 #LungCancer #PancreaticCancer

8 浏览 · 0 赞 · 0 转发 · 0 回复

会议摘要

2551TIPNCT07541170 NCT07541170 NCT07541170按 NSCLC, early stage 对上

Krascendo 3: A randomised, phase III trial in progress of divarasib vs immunotherapy or observation in patients with resected, stage II-IIIB, KRAS G12C+ non-small cell lung cancer

https://esmocongress.esmo.org

LBA5NCT06497556按 KRASCENDO-1 对上

KRASCENDO-1

https://esmocongress.esmo.org

NCT06497556NCT06497556按 KRASCENDO-1 对上

KRASCENDO-1

https://esmocongress.esmo.org

来源：Oncology Nursing News · x.com